(Entertainment Industry Foundation) SU2C and St. Baldrick's welcomed ODAC's recommendation for FDA approval of the new CAR T therapy for a deadly form of leukemia, an approach whose development has also been supported by their Pediatric Dream Team investigating why some patients with B-cell ALL relapse after receiving the CD19 CAR T cell therapy, and developing standardized management of cytokine release syndrome (CRS), a potentially fatal side effect of the treatment.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2ukboxq
No comments:
Post a Comment